Abstract:
INTRODUCTION:Pharmaceutical companies and the NIH have invested heavily in a variety of potential disease-modifying therapies for Alzheimer's disease (AD) but unfortunately all double-blind placebo-controlled Phase III studies of these drugs have failed to show statistically significant results supporting their clinical efficacy on cognitive measures. These negative results are surprising as most of these medications have the capability to impact the biomarkers which are associated with progression of Alzheimer's disease. Areas covered: This contradiction prompted us to review all study phases of Intravenous Immunoglobulin (IVIG), Bapineuzumab, Solanezumab, Avagacestat and Dimebolin to shed more light on these recent failures. We critically analyzed these studies, recommending seven lessons from these failures which should not be overlooked. Expert commentary: We suggest a new methodology for future treatment research in Alzheimer's disease considering early intervention with more focus on cognitive decline as a screening tool, more sophisticated exclusion criteria with more reliance on biomarkers, stratification of subjects based on the rate of cognitive decline aiming less heterogeneity, and a longer study duration with periodic assessment of cognition and activities of daily living during the study and also after a washout period.
journal_name
Expert Rev Neurotherjournal_title
Expert review of neurotherapeuticsauthors
Amanatkar HR,Papagiannopoulos B,Grossberg GTdoi
10.1080/14737175.2016.1194203subject
Has Abstractpub_date
2017-01-01 00:00:00pages
7-16issue
1eissn
1473-7175issn
1744-8360journal_volume
17pub_type
杂志文章,评审abstract:INTRODUCTION:Mental illness has a chronic course of illness with a number of clinical manifestations. Affected individuals experience significant functional, emotional, cognitive, and/or behavioral impairments. The growing prevalence of mental illness has been associated with significant social and economic costs. Inde...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1080/14737175.2020.1826931
更新日期:2020-12-01 00:00:00
abstract::Advances in molecular biology and virology in recent years have enabled the technology of gene transfer to proceed forward. Parkinson's disease (PD) is a particularly appropriate target for gene therapy since the brain pathology is fully characterized and relatively well circumscribed largely within the nigrostriatal ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.7.8.957
更新日期:2007-08-01 00:00:00
abstract::Introduction: Vitamin B6 dependent epilepsies are a group of treatable diseases (ALDH7A1 deficiency, PNPO deficiency, PLP binding protein deficiency, hyperprolinaemia type II and hypophosphatasia and glycosylphosphatidylinositol anchor synthesis defects) responding to pyridoxine or pyridoxal-5I-phosphate. Areas covere...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1080/14737175.2019.1648212
更新日期:2019-11-01 00:00:00
abstract::Spasticity is a common complication of CNS injury and a cause of considerable discomfort and disability for the patient and difficulty for caregivers. It is estimated that over half a million people in the USA are affected by spasticity. In recent years, advances in the treatment of spasticity include the use of intra...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1586/14737175.3.6.773
更新日期:2003-11-01 00:00:00
abstract::Median survival of patients with malignant glioma (MG) from time of diagnosis is approximately 1 year, despite surgery, irradiation and conventional chemotherapy. Improving patient outcome relies on our ability to develop more effective therapies that are directed against the unique molecular aberrations within a pati...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.09.116
更新日期:2009-12-01 00:00:00
abstract::Primary brain tumors are generally difficult to treat because of the unique location of the lesions. In addition, normal brain structures are often destroyed by the growing neoplasm. Even with effective therapy to surgically resect and destroy the neoplastic tissues, the brain is sometimes still injured, which can lea...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.6.5.723
更新日期:2006-05-01 00:00:00
abstract::The 10th Global College of Neuroprotection and Neuroregeneration Annual Conference in collaboration with the 6th International Association of Neurorestoratology VI Intercontinental Hotel, Bucharest, Romania, 4-7 April 2013 The 10th Global College of Neuroproetction and Neuroregeneration Annual Conference together with...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1586/14737175.2013.836297
更新日期:2013-10-01 00:00:00
abstract::Over the last decade, much progress has been made towards identifying risk factors for schizophrenia. It is now thought that many genes of small effect contribute towards risk of developing schizophrenia and some of these probably confer susceptibility to environmental factors. Large population-based studies, using re...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1586/14737175.1.2.183
更新日期:2001-11-01 00:00:00
abstract::Cognitive dysfunction (CD) affects 40-65% of multiple sclerosis (MS) patients and can have a great functional impact. It can be detected in all the disease phenotypes from the early stages of the disease and tends to progress over time. Memory, complex attention, information processing speed and executive functions ar...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.8.10.1585
更新日期:2008-10-01 00:00:00
abstract::Post-traumatic headache (PTH) is a very controversial disorder, particularly when it comes to chronic PTH following mild closed head injury and headache attributed to whiplash injury. Nevertheless, mild traumatic brain injury is very common in Western societies, affecting approximately 1.8 million individuals in the U...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.09.84
更新日期:2009-09-01 00:00:00
abstract::Understanding of the structure and function of the endocannabinoid system is rapidly evolving. Physiological and pharmacological manipulations based on cannabinoid receptors, ligands and endocannabinoids have explained some medicinal attributes of cannabinoids as used across the world for thousands of years. Plant-der...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1586/14737175.1.1.92
更新日期:2001-09-01 00:00:00
abstract:INTRODUCTION:Therapy with current antiepileptic drugs aims at reducing the likelihood of seizure occurrence rather than influencing the underlying disease process. Therefore, antiepileptic drugs have an anticonvulsant rather than antiepileptic property. Areas covered: The increasing identification of genetic causes for...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1080/14737175.2017.1253476
更新日期:2017-04-01 00:00:00
abstract::There is great concern over cardiovascular disease in the schizophrenic population owing to the high incidence of cardiovascular mortality. Increased cardiovascular mortality is related to lifestyle choices (e.g., smoking and sedentary lifestyle) and a high prevalence of comorbid medical conditions, including dyslipid...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.7.7.829
更新日期:2007-07-01 00:00:00
abstract::Management issues for patients with brain tumors include peritumoral edema, symptomatic seizures, venous thromboembolism, headache, pain, fatigue and neuropsychological complaints. Vasogenic edema is typically ameliorated with the lowest dose possible of corticosteroid. Seizures are managed with attention to additiona...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.7.10.1327
更新日期:2007-10-01 00:00:00
abstract::Introduction: Brivaracetam (BRV) is an analog of levetiracetam (LEV) with 15-30 times greater affinity to SV2A and greater brain permeability than LEV. These properties have stimulated interest in its clinical trial data and post-marketing experience. Areas covered: The authors provide a background on epilepsy and its...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1080/14737175.2019.1631160
更新日期:2019-10-01 00:00:00
abstract::Recent morphometric MRI studies have investigated brain volume abnormalities associated with the diagnosis of Alzheimer's disease (AD) using voxel-based morphometry (VBM). This technique allows the assessment of gray matter volumes in subjects with AD or related conditions compared with healthy controls in an automate...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.8.11.1691
更新日期:2008-11-01 00:00:00
abstract::The prevalence rate of chronic pain is 15% to 25% in adults while the therapeutic arsenal is still insufficient, especially in relieving neuropathic pain. Peripheral pain transmission is conducted by the small Aδ and C sensory nerve fibres. They express elements from the renin-angiotensin-aldosterone system (RAAS), a ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.2016.1150179
更新日期:2016-01-01 00:00:00
abstract::The risk of recurrent stroke following transient ischemic attack or minor stroke has recently been shown to be 5-10% at 1 week and 10-20% at 3 months, depending on study population and methods. This is considerably higher than previously estimated and current clinical guidelines reflect the need for rapid assessment a...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.5.2.203
更新日期:2005-03-01 00:00:00
abstract::Divalproex sodium has been widely use for the treatment of bipolar disorder, behavioral control in schizophrenia, seizure and agitation in Alzheimer's disease. With the advent of other mood stabilizers and anticonvulsants, the use of divaplroex sodium has been slightly decreased; however, it has been a major mediation...
journal_title:Expert review of neurotherapeutics
pub_type: 评论,杂志文章
doi:10.1586/ern.11.194
更新日期:2012-02-01 00:00:00
abstract::Constituents of the Cannabis plant, cannabinoids, may be of therapeutic value in neurologic diseases. The most abundant cannabinoids are Δ(9)-tetrahydrocannabinol, which possesses psychoactive properties, and cannabidiol, which has no intrinsic psychoactive effects, but exhibits neuroprotective properties in preclinic...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.2014.985209
更新日期:2014-12-01 00:00:00
abstract::Cognitive-behavioral therapy (CBT) originated as a treatment for emotional disorders. However, it is increasingly used to help people with chronic illnesses manage symptoms and improve psychosocial outcomes, such as depression and quality of life. In this article, we focus on uses of CBT in patients with multiple scle...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.10.111
更新日期:2010-09-01 00:00:00
abstract::Advances in neuroscience have led to an expanded and improved understanding of neurobiological changes associated with rehabilitation and exercise in Parkinson's disease (PD). This knowledge has led to a direct clinical impact of increased referral for early and continuous exercise programs for individuals with PD (ph...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.11.43
更新日期:2011-06-01 00:00:00
abstract::Generalized anxiety disorder is characterized by excessive chronic anxiety in association with many somatic symptoms. The disorder has pervasive effects on quality of life, including work, social and educational aspects and requires long-term therapy. Available studies in patients are the Diagnostic and Statistical Ma...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.4.2.285
更新日期:2004-03-01 00:00:00
abstract::Narcolepsy is a life-long neurodegenerative disorder that causes considerable impairment to quality of life. Until the 1970s, the treatment for one of the main symptoms, excessive daytime sleepiness, was restricted to stimulants, whereas the second core symptom, cataplexy, was treated with antidepressants, and the res...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.12.42
更新日期:2012-05-01 00:00:00
abstract::Developing new treatment strategies for acute ischemic stroke in the last twenty years has offered some important successes, but also several failures. Most trials of neuroprotective therapies have been uniformly negative to date. Recent research has reported how excitatory amino acids act as the major excitatory neur...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.2015.1101345
更新日期:2015-01-01 00:00:00
abstract::Advances in research and better understanding of the pathophysiology of diseases have resulted in an increase in the number of available health interventions that compete for finite public resources. Explicit choices must therefore be made about funding. ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.2013.865872
更新日期:2013-12-01 00:00:00
abstract::Non-pharmacological interventions have the potential to reduce cognitive decline and to improve psychosocial aspects in mild cognitive impairment and Alzheimer's dementia, and the absence of side effects makes them a favorable option also for preventive strategies. We provide an overview on recent studies involving co...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.2013.845086
更新日期:2013-11-01 00:00:00
abstract::Research has shown that structural variation in the human genome, including rare copy number variations (CNVs), contributes to genetic susceptibility to psychiatric diseases, such as schizophrenia, a devastating complex disorder with a high genetic load. The study by Vacic et al. applied a genome-wide approach to dete...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.11.84
更新日期:2011-07-01 00:00:00
abstract::Introduction: Almotriptan (ALT), a serotonin 5-HT1B/1D agonist has been used in the acute treatment of migraine with or without aura for 20 years, accumulating data on more than 15,000 patients in studies and from an estimated >150 million treated migraine attacks in daily clinical practice. The last major review of A...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1080/14737175.2019.1591951
更新日期:2019-08-01 00:00:00
abstract::Alzheimer's disease (AD) is the most common cause of dementia and is characterized by an insidious onset and slow deterioration in cognition, activities of daily living (ADL), mood stability and social functioning. The cholinesterase inhibitors (ChEIs), developed based on the cholinergic hypothesis, are currently cons...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.09.23
更新日期:2009-05-01 00:00:00